

Supplementary Fig. 2. The glucose-lowering efficacy in each treatment group. (A) Changes in glycosylated hemoglobin (HbA1c) for 24 weeks, (B) proportion of patients achieving HbA1c (\leq 7%) targets at 24 weeks. Data are presented as mean \pm standard error (SE). GLP-1RA, glucagon-like peptide-1 receptor agonist.